Sorry, you need to enable JavaScript to visit this website.
移至主內容

我們的公司

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
CT -  Taipei City
CT -  Taipei City
TH -  Bangkok
NZ -  New Zealand
KR -  Seoul (Gangnam)
KR -  Gyeonggi-do
KR -  Seoul City Airport

North America

US -  Boston
US -  South Carolina

GLOBAL

English

CAREERS

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
CT -  Taipei City
CT -  Taipei City
TH -  Bangkok
NZ -  New Zealand
KR -  Seoul (Gangnam)
KR -  Gyeonggi-do
KR -  Seoul City Airport

North America

US -  Boston
US -  South Carolina

GLOBAL

English

NOVOTECH 是國際認可的領先區域性主要受託研究機構 (CRO)。

Novotech 在亞太地區 11 處分別設有辦公室, 並與重要醫學機構締結試驗場地夥伴關係。

Novotech 提供所有臨床試驗階段的臨床開發服務,治療的領域包括:可行性評估;研究倫理委員會與法規審核送件、資料管理、統計分析、醫學監測、安全性解決方案、中央實驗室服務、ICH 需求報告登載、專案與廠商管理。Novotech 已獲得 ISO 27001 認證,這是 ISO 系列中知名的資訊安全管理系統標準。連同 ISO 9001 品質管理系統,Novotech 鎖定為患者提供以及為生技業樹立最高的 IT 安全性與品質標準。

關於諾威健康集團 (NOVOTECH HEALTH HOLDINGS)

Novotech 是亞太地區首屈一指的生技專業 CRO,旗下有二個營運品牌 「Novotech」和「PPC」。Novotech 的臨床 CRO 具備實驗室、第 I 期設施,以及藥物開發諮詢服務。已經累積逾 3,700 個臨床專案經驗,範圍涵蓋第 I 期到第 IV 期臨床試驗,以及生體相等性試驗。Novotech 專門鎖定服務生物製藥客戶進行亞洲和全球臨床試驗。截至 2021 年 9 月 30 日,Novotech 在亞太地區 11 處以及美國的辦公室共有逾 2,000 名全職員工 (FTE)。

我們的公司

我們對於自家公司強勁業績成長感到驚喜振奮。但是我們仍然高度專注於我們的核心使命,專為亞太地區生技業試驗委託者進行試驗的全方位服務 CRO。亞洲存在文化、語言,還有法規差異,環境高度異質。我們的策略核心之一,就是在每個業務營運的國家中委任有豐富經驗的在地領袖、遵守符合在地現行法規,以及實施存在監測。我們的同仁深刻瞭解當地環境,並具備優異的英語能力。

- John Moller 博士

Novotech CRO 執行長

Where We operate

  • Asia-Pacific
  • North America
Australia

Australia

  • High quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund
Greater China

Greater China

  • Very large, homogenous population
  • Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
  • Largest clinical trial hub in Asia, with over 17,000 active investigators 
     
India

India

  • Large treatment-naïve population
  • High disease population load
  • The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
  • About 1,800 investigators have participated on a minimum of 5 studies
Malaysia

Malaysia

  • Multiethnic Asian population
  • Streamlined regulatory system and Strong govt. support 
  • Quick start-up timelines
  • Low patient costs and IRB fees
Philippines

Philippines

  • Large treatment-naïve population
  • Low costs
  • Overall good level of English
Singapore

Singapore

  • Multiethnic Asian population 
  • Regional clinical research hub
  • Efficient regulatory process and good infrastructure
South Korea

South Korea

  • Homogenous and concentrated population 
  • High quality medical services and excellent infrastructure
  • The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018
Thailand

Thailand

  • Large homogenous population 
  • High prevalence of communicable diseases
  • Efficient regulatory system
  • Low operational cost
United States of America

United States of America

As part of a service expansion program, Novotech has acquired US CRO NCGS, a full service CRO managing clinical trials since 1984 and can now offer CRO services to biotech clients in the US to support early and late phase global studies.

New Zealand

New Zealand

  • High-quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund